GCP
MCRB icon

GSA Capital Partners’s Seres Therapeutics MCRB Stock Holding History

GSA Capital Partners’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-10,001
Closed -$1.39M – 1638
2021
Q3 		$1.39M Buy
+10,001
New +$1.96M 0.14% 157
2020
Q3 		– Sell
-712
Closed -$68K – 1330
2020
Q2 		$68K Buy
+712
New +$62.5K 0.04% 524
2016
Q3 		– Sell
-470
Closed -$273K – 1873
2016
Q2 		$273K Buy
+470
New +$276K 0.02% 1432

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

GSA Capital Partners's MCRB Position: Q4 2021 in Review

GSA Capital Partners sold out of Seres Therapeutics (MCRB) in Q4 2021, closing a stake of 10,001 shares — an estimated $1.39M sold.

GSA Capital Partners first reported a position in MCRB in Q2 2016 and held it in 3 quarters. The position peaked at $1.39M in Q3 2021. 148 funds tracked by Wall St. Rank hold MCRB as of Q4 2021.

  • GSA Capital Partners reported no remaining Seres Therapeutics position as of Q4 2021 after selling out during the quarter.
  • GSA Capital Partners sold 10,001 Seres Therapeutics shares in Q4 2021, an estimated $1.39M.
  • GSA Capital Partners first reported a position in Seres Therapeutics in Q2 2016 and held it in 3 quarters.
  • GSA Capital Partners's Seres Therapeutics position peaked at $1.39M in Q3 2021.
  • 148 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2021.

Based on GSA Capital Partners's 13F filing for Q4 2021, filed 14 Feb 2022.